Go offline with the Player FM app!
🧬 Amylin & GLP-1: Double Agents for Weight Loss & DM-CagriSema (Part II)
Manage episode 491157452 series 2740117
🚨 Major breakthrough in obesity pharmacotherapy!
The REDEFINE-1 & REDEFINE-2 trials show that once-weekly CagriSema (Cagrilintide + Semaglutide) delivers up to 20% weight loss in people with obesity—and significant glycemic improvements in those with type 2 diabetes. 💉📉
🌍 Global, double-blind RCTs
⚖️ >90% lost ≥5% body weight
🩺 SBP ↓, QoL ↑, prediabetes reversed in 88%
⚠️ GI side effects common but mostly mild
💡 CagriSema is redefining the weight loss frontier—with dual satiety and metabolic action.
#Obesity #GLP1 #Cagrilintide #Semaglutide #CagriSema #WeightLoss #RCT #MetabolicHealth #Prediabetes #NovoNordisk #Endocrinology #InternalMedicine #PrecisionMedicine #Pharma #ClinicalTrials #ObesityMedicine #Amylin #GLP1Agonist #T2D #LifestyleMedicine
535 episodes
Manage episode 491157452 series 2740117
🚨 Major breakthrough in obesity pharmacotherapy!
The REDEFINE-1 & REDEFINE-2 trials show that once-weekly CagriSema (Cagrilintide + Semaglutide) delivers up to 20% weight loss in people with obesity—and significant glycemic improvements in those with type 2 diabetes. 💉📉
🌍 Global, double-blind RCTs
⚖️ >90% lost ≥5% body weight
🩺 SBP ↓, QoL ↑, prediabetes reversed in 88%
⚠️ GI side effects common but mostly mild
💡 CagriSema is redefining the weight loss frontier—with dual satiety and metabolic action.
#Obesity #GLP1 #Cagrilintide #Semaglutide #CagriSema #WeightLoss #RCT #MetabolicHealth #Prediabetes #NovoNordisk #Endocrinology #InternalMedicine #PrecisionMedicine #Pharma #ClinicalTrials #ObesityMedicine #Amylin #GLP1Agonist #T2D #LifestyleMedicine
535 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.